by Heidi Hagen and Christophe Suchet | February 11, 2020
This post is the fifth in an eight-part series on data management strategies for personalized therapeutics, such as cell therapies, gene therapies, or neoantigen cancer vaccines.
by Amy DuRoss and Heidi Hagen | February 5, 2020
On February 5th, 2020, we announced Vineti’s $35 million Series C round of investment. A first-of-its-kind investor coalition of industry leaders -- Cardinal Health, Novartis Pharma AG, and Kite, a Gilead Company -- came together with our current…
by Heidi Hagen and Christophe Suchet | January 30, 2020
Vineti created this series of blog posts and in-depth data management whitepaper to help those developing personalized therapeutics.
by Amy DuRoss | January 15, 2020
Vineti, Inc., the provider of the leading digital platform of record for personalized therapeutics, today announced the appointment of John Kontor, M.D. to the company’s Board of Directors. Dr. Kontor, a clinical leader with deep experience in both…
by Heidi Hagen and Christophe Suchet | January 8, 2020
This post is the third in an eight-part series on data management strategies for personalized therapeutics, such as cell therapies, gene therapies, or neoantigen cancer vaccines.